secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001564590-21-043086
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma Q2 cash $44.1M; sarcoidosis data readout expected mid-September
---------------------------------------------------------------------------

- Cash, equivalents and investments $44.1M as of June 30, 2021; R&D expense $7.7M, G&A $2.8M.
- Last patient visit completed in Phase 1b/2a study of ATYR1923 in pulmonary sarcoidosis; data due mid-September 2021.
- Kyorin completed Phase 1 study of ATYR1923 in 32 Japanese volunteers; safe, well-tolerated, PK consistent.
- Appointed Sara Zaknoen, M.D. to board; received US patent for ATYR1923 lung inflammation methods.
- Shares outstanding 16.9M as of Aug 9, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459021043086/0001564590-21-043086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459021043086/life-8k_20210810.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-043086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer